Comparing the current results to its competitors, Prometheus Biosciences Inc reported Revenue decrease in the 3 quarter 2023 year on year by -71.8 %, despite the revenue increase by the most of its competitors of 8.85 %, recorded in the same quarter.
Prometheus Biosciences Inc , slower than the average decrease reported by the company's competitors of -44.82 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -44.82 %
Publicly Traded Peers of Prometheus Biosciences Inc
Nascent Biotech Inc Share Performance
-50.00%
This Year
Nascent Biotech Inc
Profile
Nascent Biotech Inc's business model is focused on the development and commercialization of innovative therapies in the field of biotechnology. They aim to leverage their expertise and research to bring new drugs to market that can address critical unmet medical needs.
AstraZeneca Plc is a global biopharmaceutical company focused on the research, development, and commercialization of innovative medicines. Their business model involves investing extensively in research and development to discover novel treatments for a wide range of diseases. AstraZeneca then markets and sells these medicines globally, collaborating with healthcare providers and leveraging their strong sales and distribution networks.
Viatris Inc operates as a global pharmaceutical company, specializing in the development, manufacturing, and distribution of a wide range of generic and branded medicines, as well as biosimilars.
Teva Pharmaceutical Industries Limited is a multinational pharmaceutical company that focuses on the development, production, and marketing of generic and specialty medicines. They aim to provide affordable and accessible healthcare solutions to patients worldwide.
Regeneron Pharmaceuticals Inc operates a business model centered on the discovery and commercialization of cutting-edge biopharmaceuticals, particularly in the fields of ophthalmology, oncology, immunology, and rare diseases. They leverage their strong research and development capabilities, including their proprietary technologies, to create innovative therapies that address unmet medical needs. Additionally, Regeneron forms strategic collaborations and partnerships to enhance their development pipeline and expand market access for their products.
Sources:
Prometheus Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Prometheus Biosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
